Novartis May Copy Syngenta's Model To Improve Shareholder Value

News: Swiss drugmaker Novartis, which recently launched a review of its underperforming businesses, may follow the model used by agrochemicals company Syngenta to enhance value for shareholders, according to Novartis' board member Pierre Landolt. Syngenta was created in 2000 through a combination of spin-offs and mergers of Novartis' agrochemical and seed divisions, and the agrochemicals and biotechnology research divisions of Anglo-Swiss drugmaker AstraZeneca. According to Landolt, Novartis could use such a model in markets where it is seeking to expand its business footprint. Syngenta is currently the world's biggest player in agrochemicals with a market value of US$38bn.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Switzerland

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.